Immunome, Inc. develops targeted cancer therapies through a clinical-stage oncology pipeline that includes varegacestat, an investigational oral gamma secretase inhibitor for desmoid tumors, IM-1021, a ROR1 antibody-drug conjugate, and IM-3050, a FAP-targeted radiotherapy. Company news commonly covers clinical data, regulatory submissions, IND-related progress, oncology conference presentations, and updates on antibody-drug conjugate programs for solid tumors.
Recurring corporate updates also include financial results, business progress reports, investor conference participation, equity compensation actions under the 2024 Inducement Plan, and Nasdaq Listing Rule 5635(c)(4) inducement grants for new employees.
Immunome (Nasdaq: IMNM) said management will present at two investor conferences in March 2026: TD Cowen on March 3, 2026 at 9:50 a.m. ET and Leerink Partners on March 10, 2026 at 3:00 p.m. ET.
According to Immunome, live audio webcasts will be available via the company’s Investor Relations website and replays will remain accessible for approximately 30 days after each presentation.
Immunome (Nasdaq: IMNM) disclosed that on February 2, 2026 its Compensation Committee granted inducement non-statutory stock options for an aggregate of 30,000 shares to one new employee under the 2024 Inducement Plan.
The options have an exercise price of $26.14, equal to the February 2, 2026 closing price, and vest over four years with standard 25% one-year cliff and monthly vesting thereafter.
Immunome (NASDAQ: IMNM) will present at Guggenheim's Emerging Outlook: Biotech Summit on February 11, 2026 at 9:00 a.m. ET.
Investors can access a live audio webcast via the company Investor Relations website at www.immunome.com; a replay will be available for approximately 30 days after the presentation.
Immunome (Nasdaq: IMNM) announced that on January 2, 2026 its Compensation Committee granted inducement non‑statutory stock options covering an aggregate of 93,000 shares to three new employees under the company’s 2024 Inducement Plan.
The options have an exercise price of $20.82 per share (the closing price on January 2, 2026) and vest over four years with 25% vesting at the one‑year anniversary and the remainder vesting monthly over the following 36 months, subject to continued service. Grants are subject to the 2024 Inducement Plan and individual option agreements.
Immunome (Nasdaq: IMNM) announced management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 10:30 a.m. PST.
Interested parties can access a live audio webcast via the company Investor Relations website at www.immunome.com. A replay webcast will be available for approximately 30 days following the live presentation.
Immunome (Nasdaq: IMNM) priced an underwritten public offering of 18,625,000 shares of common stock at $21.50 per share, with gross proceeds to the company of approximately $400 million. The underwriters have a 30-day option to purchase up to an additional 2,793,750 shares at the public offering price (the 15% overallotment).
The offering is expected to close on December 18, 2025, subject to customary closing conditions. Joint bookrunners include Leerink Partners, J.P. Morgan, TD Cowen, Goldman Sachs & Co. and Guggenheim Securities.
Immunome (Nasdaq: IMNM) announced a proposed underwritten public offering of $400 million of common stock, with Immunome offering all shares and a 30-day underwriter option to purchase up to an additional $60 million.
The offering is subject to market and other conditions and may not be completed as proposed. Joint bookrunning managers are Leerink Partners, J.P. Morgan, TD Cowen, Goldman Sachs & Co. and Guggenheim Securities; co-leads are Wedbush PacGrow and LifeSci Capital. The offering will be made from a Form S-3 shelf registration that became effective on February 13, 2024, and a preliminary prospectus supplement will be filed with the SEC.
Immunome (Nasdaq: IMNM) reported positive topline Phase 3 RINGSIDE results for oral varegacestat in progressing desmoid tumors. The trial met the primary endpoint with a progression-free survival HR = 0.16 (84% risk reduction; 95% CI: 0.071–0.375; p<0.0001). Confirmed objective response rate was 56% vs. 9% for placebo (p<0.0001). Exploratory median best tumor volume change was -83% vs. +11% for placebo. Key secondary endpoints, including landmark tumor reduction and worst pain, were met. Varegacestat was generally well tolerated; common AEs included diarrhea (82%), fatigue (44%) and rash (43%). NDA planned for Q2 2026.
Immunome (Nasdaq: IMNM) will disclose topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat in patients with progressing desmoid tumors on Monday, December 15, 2025.
The company will host a live webcast and conference call on December 15, 2025 at 8:30 a.m. ET (5:30 a.m. PT) that includes presentation slides and a live Q&A following prepared remarks. The webcast is listen-only; questions must be asked via the conference call. The webcast will be archived on Immunome's investor website for 90 days.
Immunome (Nasdaq: IMNM) announced that on December 1, 2025 its Compensation Committee granted inducement non‑statutory stock options to four new employees totaling 88,000 shares under the Company’s 2024 Inducement Plan.
Each option has an exercise price of $18.32 per share (the company’s closing price on December 1, 2025) and vests over four years: 25% at the one‑year anniversary and the remainder monthly over the following 36 months, subject to continued service and the plan and option agreement terms.